<DOC>
	<DOCNO>NCT00573443</DOCNO>
	<brief_summary>Objectives study evaluate safety , tolerability , efficacy two different dos AVP-923 ( capsule contain either 30 mg dextromethorphan hydrobromide 10 mg quinidine sulfate [ AVP-923-30 ] 20 mg dextromethorphan hydrobromide 10 mg quinidine sulfate [ AVP-923-20 ] ) compare placebo , treatment PBA population patient amyotrophic lateral sclerosis ( ALS ) multiple sclerosis ( MS ) 12-week period . An additional objective determine pharmacokinetic parameter two different dos AVP-923 subset study population . Pseudobulbar Affect ( PBA ) condition characterize involuntary , sudden frequent episode laugh and/or cry proportion incongruous underlie emotion happiness sadness Other term use describe condition include emotional lability , emotionalism , emotional incontinence , emotional discontrol , excessive emotionalism , pathological laugh cry . The outburst occur spontaneously response provocative stimuli question event . A body evidence suggest PBA modulate pharmacologic intervention . Dextromethorphan ( DM ) low-affinity uncompetitive antagonist N-Methyl-D-aspartate ( NMDA ) receptor , reduce level excitatory activity . DM also act phencyclidine-binding site , part NMDA receptor complex . DM sigma receptor agonist , suppress release excitatory neurotransmitter . Quinidine ( Q ) know potent inhibitor cytochrome P450 2D6 ( CYP2D6 ) , decrease metabolism dextromethorphan help achieve sustain therapeutic level drug .</brief_summary>
	<brief_title>Safety Efficacy AVP-923 PBA Patients With ALS MS</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>Main The patient diagnosis Amyotrophic Lateral Sclerosis ( accord El Escorial Criteria , WFN , 1998 ) time diagnosis ALS longer 30 month , patient diagnosis multiple sclerosis probable multiple sclerosis ( accord McDonald criterion , 2001 ) The patient clinical history clinical relevant symptom Pseudobulbar Affect ( PBA ) CNSLS score baseline 13 great Main Patients myasthenia gravis Any personal history complete heart block , QTc prolongation , torsades de point Any family history congenital QT interval prolongation syndrome Patients know sensitivity quinidine , dextromethorphan opiate drug ( codeine , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis ( Lou Gehrig 's disease , ALS )</keyword>
	<keyword>Multiple Sclerosis ( MS )</keyword>
</DOC>